Lupus最新文献

{"title":"2019 EULAR/ACR classification criteria for SLE score predicts future lupus hospital admission and costs.","authors":"Saurav Suman, Hammad Ali, Connor R Buechler, Heidi C Rogers, W Neal Roberts","doi":"10.1177/09612033241310071","DOIUrl":"10.1177/09612033241310071","url":null,"abstract":"<p><strong>Objective: </strong>To test the ability of the 2019 EULAR/ACR Classification Criteria for SLE score to predict lupus related hospitalization and overall cost of hospitalization.</p><p><strong>Methods: </strong>217 University of Kentucky patient records that met our preliminary inclusion criteria, 44 patients were selected by a random number generator algorithm for a thorough chart review to collect data needed for calculation of the 2019 EULAR/ACR Classification Criteria for SLE score. Total hospitalization cost was calculated by using hospital adjusted expenses per inpatient day data, which estimates the expense incurred by the hospital to provide services and thus removes the variability of charges and reimbursements introduced by insurance type.</p><p><strong>Results: </strong>Patients with a score of 19 or more had increased risk of hospitalization in at least the 6 months after initial outpatient visit as compared to their counterparts with scores less than 19 [<i>p</i>= .069]. The odds of being hospitalized for lupus among those with initial score ≥19 was 5.71 times higher than for those with score <19. Patients who scored 19 or less at initial visit had a mean hospitalization cost of $14,499, whereas those scored >19 had mean hospitalization cost of $28,725.</p><p><strong>Conclusion: </strong>This study adds to the growing evidence that 2019 EULAR/ACR Classification Criteria score for SLE can be used as a surrogate marker to assess disease severity. The weighted 2019 EULAR/ACR Classification Criteria for SLE score offers a promising tool beyond its primary objective to find true lupus cases for research and clinical trials.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"178-180"},"PeriodicalIF":1.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11780967/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142864793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lupus and SARS-CoV-2: What have we learned after the pandemic?","authors":"Rachele Francese, Massimo Rittà, David Lembo, Manuela Donalisio","doi":"10.1177/09612033241309845","DOIUrl":"10.1177/09612033241309845","url":null,"abstract":"<p><p>After the end of the COVID-19 public health emergency, we analysed the relationship between Systemic Lupus Erythematosous (SLE) and COVID-19 from the virologist's perspective based on recent findings. SLE and COVID-19 co-morbidity present unique challenges, as individuals with SLE may be at increased risk for severe COVID-19 illness due to immune system abnormalities and ongoing therapies. Effective management of both diseases requires careful monitoring, adherence to vaccination programs, preventive measures and approved and patient-tailored therapies. This review covers various aspects, including the clinical outcome of SLE patients infected by SARS-CoV-2, the impact of this infection on SLE onset or flare-ups and the benefits of vaccination for this population. Furthermore, this review presents the most recent recommendations on clinical management of COVID-19 in rheumatic patients, including those with SLE, discussing the currently available therapeutic options. Finally, we explore the most effective tools for SARS-CoV-2 diagnosis in autoimmune conditions and examine prognostic biomarkers in COVID-19 rheumatic patients with potential implications on their clinical oversight. By adopting a comprehensive approach, we address these complexities from the virologist's perspective, aiming to improve health care for this vulnerable population.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"117-132"},"PeriodicalIF":1.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142846981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic lupus erythematosus is a risk factor for having multiple subtypes of cutaneous lupus erythematosus.","authors":"Grace Lu, Larry Steven Brown, Benjamin F Chong","doi":"10.1177/09612033241311335","DOIUrl":"10.1177/09612033241311335","url":null,"abstract":"<p><strong>Background: </strong>Patients with cutaneous lupus erythematosus (CLE) can present with one or multiple different subtypes of CLE. There is limited understanding of the prevalence and associated risk factors for having multiple CLE subtype diagnoses.</p><p><strong>Objective: </strong>This study characterized the frequency and risk factors for having multiple CLE subtypes.</p><p><strong>Methods: </strong>This was a cross-sectional study of 319 patients with CLE enrolled in the University of Texas Southwestern Cutaneous Lupus Registry seen in outpatient dermatology clinics at the University of Texas Southwestern Medical Center and Parkland Health from January 1, 2009 to December 31, 2021. Demographic and clinical information was collected from each subject and compared using univariate and multivariable logistic regression analyses.</p><p><strong>Results: </strong>59 subjects (18.5%) were diagnosed with two or more CLE subtypes. Univariate analyses identified statistically significant differences in rates of systemic lupus erythematosus (SLE) diagnosis, history of positive anti-nuclear antibody, arthritis, renal disorder, and serositis in patients with multiple CLE subtype diagnoses. In the multivariable analysis, SLE diagnosis was found to be statistically significant.</p><p><strong>Conclusions: </strong>Our study showed that almost one out of five CLE patients have multiple CLE subtypes, with SLE diagnosis being a significant risk factor. Clinicians can monitor CLE patients for developing multiple subtypes and account for systemic manifestations and laboratory abnormalities associated with SLE.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"181-186"},"PeriodicalIF":1.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11780969/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142872276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serious infections and tuberculosis adversely impact outcomes of juvenile onset systemic lupus erythematosus in India.","authors":"Rudrarpan Chatterjee, Sarit Sekhar Pattanaik, Durga P Misra, Vikas Agarwal, Able Lawrence, Ramnath Misra, Amita Aggarwal","doi":"10.1177/09612033241309510","DOIUrl":"10.1177/09612033241309510","url":null,"abstract":"<p><strong>Background: </strong>Infections are a major cause of morbidity and mortality in juvenile systemic lupus erythematosus (SLE). We assessed the incidence and risk factors for major infections in juvenile SLE.</p><p><strong>Methods: </strong>A retrospective review of 225 patients of juvenile SLE (ACR 1997 criteria) with age <18 years visiting the rheumatology clinic at a single centre between 2000 to 2020 was done from case records and the hospital electronic health records. Serious infection was defined as the need for hospitalization, or infection resulting in disability or death. Cox regression was used to determine factors associated with a serious infection and the effect of serious infection on overall survival.</p><p><strong>Results: </strong>We reviewed 225 children (197 girls, mean age 13.89 ± 3.42 years) with a cumulative follow up of 1153.45 person-years. Eighty serious infections occurred in 63 (28% of the cohort) children at a rate of 69.35 serious infections per 1000 person-years. A second serious infection occurred in 12 children and 5 of them developed three infections.Among the cases with known etiology (78.75% of cases), bacterial infections were most common (<i>N</i> = 33) including <i>S. Aureus</i> (11)<i>, E. Coli</i> (7)<i>, K. Pneumoniae</i> (3)<i>, E. Fecalis</i> (3)<i>, S. Pneumoniae</i> (2)<i>, Acinetobacter spp.</i> (2)<i>, Citrobacter</i> (2)<i>, Salmonella</i> (2) and <i>P. Aeruginosa</i> (1). Twenty six (32.5%) opportunistic infections occurred: <i>Mycobacterium tuberculosis</i> (18), <i>Cytomegalovirus</i> (3), disseminated <i>Herpes zoster</i> (4) and invasive candidiasis (1) with 15 (83.3%) of the tuberculosis cases being extrapulmonary. On multivariate analysis, fever (HR 8.51, 1.17-61.44), gastrointestinal involvement (HR 4.73, 1.13-19.94), current steroid dose (HR 1.36,1.14-1.62), average cumulative steroid dose per year (HR 1.004, 1.002-1.005) and cyclophosphamide (HR 2.22, 1.11-4.46) were associated with serious infection.Hospitalization rates were significantly higher in those with any serious infection (Rate-ratio 2.79, 1.81-3.77) as was damage accrual (SLICC damage index 1.04 vs 0.22). Serious infection-free survival at 1 year and 5 years was 84% (79.1-89.2) and 72% (65.4-79.2). There were 19 deaths with infection attributable mortality in 10 (52.6%). Serious infection predisposed to higher overall mortality with recurrent infections conferring a hazard ratio of 36.02 (8.07-160.62).</p><p><strong>Conclusion: </strong>Serious infections are a major cause of mortality and damage in SLE. Constitutional symptoms, gastrointestinal involvement, current and cumulative steroid dose and cyclophosphamide predict serious infections. TB prophylaxis in patients with SLE should be considered in endemic areas, especially when using high-dose steroid therapy.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"193-203"},"PeriodicalIF":1.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142836989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proportion, domains, and risk factors of cognitive impairment in systemic lupus erythematosus.","authors":"Anissa Ben Bouzid, Mehdi Somai, Fatma Daoud, Ibrahim Arbaoui, Besma Ben Dhaou, Hedia Bellali, Fatma Boussema, Imene Rachdi, Zohra Aydi","doi":"10.1177/09612033251314592","DOIUrl":"10.1177/09612033251314592","url":null,"abstract":"<p><strong>Objective: </strong>Cognitive impairment (CI) in systemic lupus erythematosus (SLE) is quite common and is an important prognostic factor due to its severity. The aim of our study was to determine the proportion and type of CI in SLE and to identify associated risk factors.</p><p><strong>Methods: </strong>We performed a cross-sectional study (January - March 2022). Participants included SLE patients and controls (No-SLE). SLE patients were subdivided into those with and those without CI to identify associated risk factors. CI was defined based on the results of eight specific tests assessing various cognitive functions, with MMSE used for overall cognitive assessment. Impairment was indicated by abnormalities in at least five of these eight functions.</p><p><strong>Results: </strong>Our study included 60 lupus and 40 non-lupus participants. The median disease duration of patients in the SLE group was 72 months (interquartile range: 24 - 150 months). The proportion of cognitive impairment in SLE was 31.7%. The comparative study of cognitive functions between the two groups of participants with and without SLE concluded that executive functions and verbal fluency were more impaired in the lupus group compared to the non-lupus group. It also concluded that there were no statistically significant differences in attention and concentration, episodic memory, working memory, calculation, visuospatial and visuoconstructive activity, or judgement. In the multivariate analysis, patients with SLE have a significantly higher risk of CI (Adjusted OR 3.76, 95% CI: 1.217 - 11.621) compared to non-SLE individuals. Each additional year of age increases the risk by 4.4% (Adjusted OR 1.044, 95% CI: 1.008 - 1.082). For factors associated with CI in SLE, the multivariate analysis concluded that the duration of corticosteroid therapy, by months, had an adjusted OR equal to 1.009 (CI (95%): 1.000-1.018), and the duration of education, by years, had an adjusted OR equal to 0.857 (CI (95%): 0.736-0.999).</p><p><strong>Conclusion: </strong>Screening for CI in lupus patients is important, especially for those with factors associated with these disorders such as prolonged duration of corticosteroid therapy and shortened schooling.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"157-166"},"PeriodicalIF":1.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Telitacicept for refractory cystitis associated with severe systemic lupus erythematosus: A case report.","authors":"Gui-Chen Ling, Shan Zhang, Ying-Ao Guo, Shuo Yang, Zhi-Ling Li, Jian-Yong Zhang, Jing-Jing Xie","doi":"10.1177/09612033241309838","DOIUrl":"10.1177/09612033241309838","url":null,"abstract":"<p><strong>Background: </strong>Lupus cystitis, a severe complication of systemic lupus erythematosus (SLE), presents considerable treatment challenges.</p><p><strong>Purpose: </strong>This case report describes the use of telitacicept in treating severe SLE with lupus cystitis.</p><p><strong>Research design: </strong>A single patient with lupus cystitis.</p><p><strong>Study sample: </strong>A patient with symptoms including frequent urination, urgency, and acute urinary retention.</p><p><strong>Data collection and analysis: </strong>Initial treatments included corticosteroid pulse therapy, immunoglobulin, and cyclophosphamide, which improved laboratory indicators but failed to alleviate symptoms of urinary retention. The patient was then treated with telitacicept.</p><p><strong>Results: </strong>Significant alleviation of urinary retention was observed shortly after incorporating telitacicept into the treatment regimen. The patient's condition remained stable with no relapse during the subsequent 10 months of follow-up.</p><p><strong>Conclusions: </strong>This case highlights the therapeutic potential of telitacicept for SLE patients who are unresponsive to conventional therapies, particularly those with severe manifestations such as lupus cystitis.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"187-192"},"PeriodicalIF":1.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142869529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disease features at diagnosis and changes in disease course severity among commercially insured patients with childhood-onset compared with adult-onset systemic lupus erythematosus.","authors":"Michael E Stokes, Andrea Phillips-Beyer, Qian Li","doi":"10.1177/09612033251314589","DOIUrl":"10.1177/09612033251314589","url":null,"abstract":"<p><strong>Introduction: </strong>Systemic lupus erythematosus (SLE) causes widespread inflammation and damage in affected organs. Severity is determined by the type of organ systems affected and the extent of involvement. SLE occurs in childhood or adulthood and disease severity varies according to age of onset. We compared disease features and changes in disease severity over time between childhood-onset (cSLE) and adult-onset SLE (aSLE).</p><p><strong>Methods: </strong>Patients 0-64 years old, newly diagnosed with SLE during 2014-2020 were identified using the MarketScan® database. A validated algorithm was used to assess disease severity. Improving severity versus baseline was defined as a transition from a higher (severe) to a lower (mild/moderate) disease state during each evaluation period. Group comparisons were made using the Pearson chi-square test for categorical and <i>t</i> test for continuous measures.</p><p><strong>Results: </strong>A total of 10,912 patients were included. Most (89.9%) were female with a mean age of 14.2 versus 44.6 years for cSLE and aSLE groups, respectively. Patients with cSLE were more likely to have severe disease at diagnosis (38.3% vs 10.7%; <i>p</i> < .0001) versus aSLE. The largest reduction in SLE severity occurred during 6 to <12 months post-index with cSLE experiencing the greatest improvement (36.7% vs 19.9%; <i>p</i> < .0001) compared with aSLE. However, despite improvements observed over time in cSLE, this group was still more likely to have severe disease at 0 to <6 months (26.4% vs 10.5%) and 6 to <12 months (14.4% vs 8.6%) post-index compared with aSLE patients (<i>p</i> < .01, all). For aSLE, the proportions of patients experiencing either an improvement or deterioration in symptoms was similar during 0 to <6 months and 6 to <12 months. However, during 12 to <24 months, nearly twice as many patients in this group experienced a deterioration in symptoms (30.1%) compared to improvement (15.6%).</p><p><strong>Conclusions: </strong>Children with SLE present with greater symptom severity compared with adults. Although children were more likely to experience improvements following treatment, they had more active disease over time than aSLE patients. Disease severity remained stable for aSLE patients until the second year of follow-up, when more patients experienced a deterioration rather than improvement in symptoms.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"167-177"},"PeriodicalIF":1.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effectiveness of telitacicept in patients with systemic lupus erythematosus: A retrospective, real-world study.","authors":"Yinxiu Hu, Pengyu Wang, Xue Cao, Zhenbiao Wu, Yuan Feng","doi":"10.1177/09612033241311330","DOIUrl":"10.1177/09612033241311330","url":null,"abstract":"<p><strong>Objective: </strong>Despite some study demonstrated the effectiveness of telitacicept in patients with systemic lupus erythematosus (SLE), a noticeable gap exists in real-world data. This study aimed to examine the effectiveness and safety of telitacicept in patients with SLE in the real-world.</p><p><strong>Method: </strong>This retrospective study enrolled patients with SLE at the Tangdu Hospital from January 2022 to January 2023. These patients were administered telitacicept at 80 mg or 160 mg dosage. The observed outcomes were changes in the SLE Responder Index 4 (SRI-4), disease activity, renal function, and immunological indicators.</p><p><strong>Result: </strong>Sixty-one patients were enrolled, with 60 patients completed the 24-week follow-up, and 30 completed the 52-week. The SRI-4 response rates at 4, 12, 24, and 52 weeks were 52.5%, 67.2%, 75.4%, and 80.0%, respectively. No statistically differences were observed in the SRI-4 response rates between the 80 mg and 160 mg doses at any of the time points (all <i>p</i> > 0.05). By 52 weeks, the Safety of Estrogens in Lupus Erythematosus National Assessment-SLE Disease Activity Index scores were significant decreased from baseline (<i>p</i> < 0.001), and complement 3 and 4 levels (<i>p</i> = 0.001), albumin levels (<i>p</i> = 0.004), and the overall change in glucocorticoid dosage (<i>p</i> < 0.001) were all significantly increased, with all showing significant changes over time (<i>p</i> < 0.001). During the study, 3 (4.9%) patients experienced infection, and 1 (1.6%) developed an allergy at the injection site.</p><p><strong>Conclusion: </strong>Telitacicept exhibited a highly effective and favorable safety in patients with SLE, with improved renal and hematological manifestations and facilitated a reduction in glucocorticoid medication usage.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"133-139"},"PeriodicalIF":1.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142882201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Urinary congophilia as a predictive biomarker of lupus nephritis in pregnant and non-pregnant women with systemic lupus erythematosus.","authors":"Dalia Younis, Rasha Shemies, Mahmoud M Zakaria, Sameha A Omar, Alaa Mosbah, Ghada El-Kannishy, Alaa Sabry, Sherouk Elnagar","doi":"10.1177/09612033241312746","DOIUrl":"10.1177/09612033241312746","url":null,"abstract":"<p><strong>Background: </strong>Endoplasmic reticulum stress with protein misfolding has been introduced as a key pathogenetic mechanism in lupus nephritis (LN). Pregnancy is thought to exaggerate proteostasis, which leads to the accumulation of potentially pathogenic misfolded proteins in the urine, serum, and placenta particularly in women with preeclampsia. The detection of misfolded proteins is made using Congo red stain, which is referred to as congophilia. This study aimed to assess the predictive value of urinary congophilia as a marker of LN activity in pregnant and non-pregnant LN women.</p><p><strong>Methods: </strong>Urine samples from non-pregnant LN women (<i>n</i> = 45), pregnant LN women (<i>n</i> = 12), as well as pregnant healthy controls (<i>n</i> = 38) were collected. Urinary congophilia was assessed by Congo Red Dot Blot assay. The disease activity was defined according to SLE Disease Activity Index (SLEDAI) score, and SLE Disease Activity Index-Renal Domain (SLEDAI-R) score. Renal biopsy was done for 33 non-pregnant LN women as it was clinically indicated, and modified NIH activity index (AI) was assessed according to the classification of LN by the International Society of Nephrology/Renal Pathology Society (ISN/RPS).</p><p><strong>Results: </strong>Congo red retention (CRR) values were significantly higher for pregnant active LN patients, in comparison with pregnant inactive LN patients (<i>p</i> = .014), as well as pregnant healthy controls (<i>p</i> = .009). Additionally, CRR values were significantly higher for non-pregnant active LN patients, in comparison with non-pregnant inactive LN patients (<i>p</i> = .016), as well as pregnant healthy controls (<i>p</i> ≤ .001). There were significant positive correlations between CRR on one hand, and anti-ds-DNA (r = 0.791, <i>p</i> ≤ .001), serum creatinine (r = 0.620, <i>p</i> ≤ .001), SLEDAI score (r = 0.623, <i>p</i> ≤ .001), as well as SLEDAI-R score (r = 0.473, <i>p</i> = .005) on the other hand. A highly significant negative correlation was detected between CRR, and serum albumin (r = -0.454, <i>p</i> = .001). CRR at a cut point ≥21.85 had 83% sensitivity, and 58% specificity to capture high LN activity status (NIH-AI >10) versus lower LN activity status.</p><p><strong>Conclusion: </strong>Urinary congophilia may add a diagnostic value in patients with LN and can be a reliable marker of disease activity. CRR is related to disease activity rather than pregnancy.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"149-156"},"PeriodicalIF":1.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142921950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating how patients with lupus nephritis access and trust health information: Results from a Canadian survey of patients with lupus nephritis.","authors":"Francesca S Cardwell, Susan J Elliott, Megan Rw Barber, Kim Cheema, Sydney George, Adrian Boucher, Ann E Clarke","doi":"10.1177/09612033251313578","DOIUrl":"10.1177/09612033251313578","url":null,"abstract":"","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"217-219"},"PeriodicalIF":1.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142950818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}